Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930098 | 0.83 | KDM4E (0.54) | CYP2C19 | |
| SCHEMBL9988740 | 0.82 | NR4A2 (0.45) | NR4A2PDCD1CD274CYP2C19ADORA2A | |
| SCHEMBL11494835 | 0.82 | MMP3 (0.49) | PDCD1CD274PDK2 | |
| SCHEMBL7204765 | 0.82 | PDCD1 (0.62) | PDCD1CD274PDK2 | |
| SCHEMBL1497158 | 0.82 | CYP2C19 (0.53) | NR4A2PDCD1CD274CYP2C19ADORA2A | |
| SCHEMBL9239435 | 0.81 | CYP1A2 (0.48) | ADORA2ASLC6A4SLC6A3PTGS2PTGS1 | |
| SCHEMBL2492790 | 0.81 | PDCD1 (0.52) | PDCD1CD274PDK2FFAR1FFAR4 | |
| SCHEMBL1443992 | 0.81 | PDCD1 (0.43) | NR4A2PDCD1CD274ADORA2APDK2 | |
| SCHEMBL2390680 | 0.80 | PDCD1 (0.43) | PDCD1CD274PDK2 | |
| SCHEMBL9003585 | 0.79 | CYP2C19 (0.38) | NR4A2CYP2C19ADORA2ASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | DOTTIKON ES HOLDING AG (CH) | 2024-10-22 | — | — | US | disclosed |
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2022-01-06 | — | — | US | disclosed |
| EP-3877357-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS | DOTTIKON ES HOLDING AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | NR4A2 4030/4885PDCD1 2431/4885CD274 1498/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | NR4A2 1831/4885PDCD1 402/4885CD274 512/4885 |
| US-20220006020-A1 | DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS | NR0B2, KCNJ2, TRRAP | NR4A2 23/4885PDCD1 4094/4885CD274 3002/4885 |
| US-12127473-B2 | Di-, tri- and tetraphenylindane derivates and their use in organic electronics | NR0B2, KCNJ2, TRRAP | NR4A2 23/4885PDCD1 4094/4885CD274 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.